Patents Examined by Brian Whiteman
  • Patent number: 10487314
    Abstract: Disclosed herein are methods involving the targeting of 5HT biosynthesis in gut insulin-negative cells to convert them into insulin-positive cells. Also disclosed are methods for treating a disease or disorder in a mammal, preferably a human, associated with impaired pancreatic endocrine function, by administering a therapeutically effective amount of an enumerated active agent that reduces the expression, biosynthesis, signaling or biological activity of serotonin or increases its degradation, wherein administering comprises delivering the agent to Gut Ins? cells in the mammal. Other embodiments of the method are directed to therapy wherein an agent that significantly reduces FOXO1 expression, biosynthesis, signaling or biological activity or increases its degradation is administered in addition to the agent that reduces serotonin, or alternatively an agent that reduces FOXO1 expression is targeted to serotonin-positive gut enteroendocrine cells.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 26, 2019
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Domenico Accili, Ryotaro Bouchi
  • Patent number: 10480023
    Abstract: A blocking nucleic acid for use in reducing the abundance of a non-target micro-RNA (miRNA) in an miRNA library is provided, including: a single-stranded complementary region at one of the 5? end of the blocking nucleic acid or the 3? end of the blocking nucleic acid, that anneals with a binding region at a first end of the unwanted miRNA; a hairpin loop forming region or other double-stranded region adjacent to the complimentary region, in which all of the terminal ends of the blocking nucleic acid except one are unavailable to participate in ligase reactions. Methods and kits for using the blocking nucleic acid are also provided.
    Type: Grant
    Filed: April 10, 2016
    Date of Patent: November 19, 2019
    Assignee: HudsonAlpha Institute for Biotechnology
    Inventors: Richard M Myers, Brian S Roberts
  • Patent number: 10472630
    Abstract: The invention provides methods and compositions for treatment of spinal muscular atrophy (SMA). In one aspect of the invention, a series of compositions comprising an antisense oligonucleotide targeting the Element 1 site on the SMN2 pre-mRNA and a Morpholino backbone is disclosed. In another aspect of the invention, a method of treating SMA patients by modulating the splicing of SMN2 pre-mRNA to increase the amount of full-length SMN is disclosed. Certain embodiments of the inventive method comprise administering an E1-targeting antisense oligonucleotide, such as Morpholino based antisense oligonucleotide, to a SMA subject.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: November 12, 2019
    Assignee: The Curators of the University of Missouri
    Inventors: Christian Lorson, Erkan Osman
  • Patent number: 10466246
    Abstract: The present invention is drawn to nucleic acid aptamer based signaling polynucleotides (SPNs) for allergen detection in samples. Disclosed herein include compositions, compounds, assays and methods of using said SPNs to detect one or more allergens in a sample, particularly food allergens in a food product.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: November 5, 2019
    Assignee: DOTS TECHNOLOGY CORP.
    Inventor: Adi Gilboa-Geffen
  • Patent number: 10457940
    Abstract: Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 29, 2019
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Neil Aronin, Edith L. Pfister
  • Patent number: 10450570
    Abstract: The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof. The methods of the invention comprises administering to the subject an effective amount of a HK2 depleting agent that decreases the level of expression and/or activity of HK2. In some embodiments, the level of expression and/or activity of fibroblast growth factor receptor (FGFR), FGF ligand and/or FGF signaling is/are decreased. The invention also includes methods for diagnosing excessive vascular development and for measuring the efficacy of a treatment for an excessive vascular development in a subject in need thereof. The invention further includes a pharmaceutical composition for treating or reducing angiogenesis or lymphangiogenesis, comprising a HK2 depleting agent and a pharmaceutical acceptable carrier.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 22, 2019
    Assignee: Yale University
    Inventors: Michael Simons, Pengchun Yu
  • Patent number: 10443056
    Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 15, 2019
    Assignees: Nogra Pharma Limited, University of Miami
    Inventors: Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
  • Patent number: 10434064
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 8, 2019
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Patent number: 10435690
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: October 8, 2019
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Gang Shen
  • Patent number: 10435430
    Abstract: Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. In certain embodiments, compounds and methods useful for the modulation of ATXN-3 pre-mRNA are described. In certain embodiments, compounds and methods useful for the modulation of ATN-1 mRNA are described.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: October 8, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Thazha P. Prakash, Jiaxin Hu, Jing Liu, Dongbo Yu, David Corey, Eric E. Swayze
  • Patent number: 10428329
    Abstract: Novel processes and compositions are described which use viral capsid proteins resistant to hydrolases to prepare virus-like particles to enclose and subsequently isolate and purify target cargo molecules of interest including nucleic acids such as siRNAs and shRNAs, miRNAs, messenger RNAs, small peptides and bioactive molecules.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: October 1, 2019
    Assignee: APSE, INC.
    Inventors: Juan Pedro Humberto Arhancet, Juan P. Arhancet, Kimberly Delaney, Kathleen B. Hall, Neena Summers, Edward Oates
  • Patent number: 10422003
    Abstract: Provided are compositions and methods for detecting RNase activity.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: September 24, 2019
    Assignee: The Regents of the University of California
    Inventor: Aiming Yu
  • Patent number: 10415095
    Abstract: The invention pertains to increased LINC00473 as an indicator of a cancer involving loss or reduction in LKB1 function. LINC00473 is also provided as a therapeutic target for treating a cancer involving loss or reduction in LKB1 function. The invention provides a method of identifying a subject as having a cancer involving loss or reduction in LKB1 function based on the level of LINC00473 in the test sample obtained from the subject and administering an effective amount of a LINC00473 inhibitor to the subject to treat the cancer. The LINC00473 inhibitor can be a small-inhibitory RNA, short hairpin RNA, bifunctional RNA, antisense oligonucleotide, ribozyme, deoxyribozyme, aptamer or small molecule inhibitor. A pharmaceutical composition comprising a LINC00473 inhibitor is also provided for the treatment of a cancer involving loss or reduction in LKB1 function.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: September 17, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Lizi Wu, Zirong Chen
  • Patent number: 10407682
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene expression and/or activity, and/or modulate a HBV gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against HBV gene expression.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: September 10, 2019
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Steven Bartz, Duncan Brown, Michael Robinson
  • Patent number: 10407679
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Patent number: 10398786
    Abstract: A combination of active agents selected from a FoxM1 enhancer, an Id1 enhancer, and a JNK3 inhibitor and the uses thereof in promoting cardiomyocyte proliferation and treating heart diseases in a subject in need of the treatment.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: September 3, 2019
    Assignee: Academia Sinica
    Inventors: Patrick C. H. Hsieh, Yuan-Yuan Cheng
  • Patent number: 10400241
    Abstract: The present invention relates to antisense oligonucleotide (ASO) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (ASOs). Hybrid ASOs, part single-stranded and part double-stranded, are provided, hybridizing to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions. In this way, ASO::protein complexes may be produced that facilitate delivery of antisense DNA into target cells. Such complexes may be used to down-regulate gene expression in cells.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: September 3, 2019
    Assignee: UNIVERSITY OF GREENWICH
    Inventors: Simon Clifford Wainwright Richardson, Paul Douglas Remane Dyer, John Carlton Mitchell
  • Patent number: 10391098
    Abstract: Provided are antisense oligomers targeted against or genes associated with a biochemical pathway and/or cellular process, and related compositions and methods of using the oligomers and compositions to treat an infected mammalian subject, for example, as primary antimicrobials or as adjunctive therapies with classic antimicrobials.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: August 27, 2019
    Assignees: Board of Regents, The University of Texas System, Oregon State University
    Inventors: Bruce L. Geller, David Greenberg
  • Patent number: 10392615
    Abstract: Provided are constructs and methods for RNA promoter identification.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Paul A. Feldstein
  • Patent number: 10376536
    Abstract: An antisense oligomer capable of binding to a selected target on the ITGA4 gene transcript to modify pre-mRNA splicing in an ITGA4 gene transcript or part thereof.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 13, 2019
    Assignee: MURDOCH UNIVERSITY
    Inventors: Stephen Donald Wilton, Sue Fletcher, May Aung-Htut